nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—head and neck cancer	0.605	1	CbGaD
Lenalidomide—TNFSF11—jaw skeleton—head and neck cancer	0.0353	0.236	CbGeAlD
Lenalidomide—TNFSF11—skull—head and neck cancer	0.0219	0.147	CbGeAlD
Lenalidomide—TNFSF11—cartilage tissue—head and neck cancer	0.0187	0.125	CbGeAlD
Lenalidomide—TNFSF11—tongue—head and neck cancer	0.0113	0.0755	CbGeAlD
Lenalidomide—TNFSF11—mouth—head and neck cancer	0.00758	0.0508	CbGeAlD
Lenalidomide—TNFSF11—connective tissue—head and neck cancer	0.00465	0.0311	CbGeAlD
Lenalidomide—CDH5—parotid gland—head and neck cancer	0.00397	0.0266	CbGeAlD
Lenalidomide—CDH5—connective tissue—head and neck cancer	0.0035	0.0234	CbGeAlD
Lenalidomide—TNFSF11—lymphoid tissue—head and neck cancer	0.0034	0.0227	CbGeAlD
Lenalidomide—CDH5—epithelium—head and neck cancer	0.00332	0.0222	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—BCL2L1—head and neck cancer	0.00318	0.0588	CbGpPWpGaD
Lenalidomide—CDH5—trachea—head and neck cancer	0.00293	0.0196	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—NOTCH1—head and neck cancer	0.00281	0.0519	CbGpPWpGaD
Lenalidomide—CDH5—Adherens junctions interactions—CDH1—head and neck cancer	0.00279	0.0516	CbGpPWpGaD
Lenalidomide—TNFSF11—head—head and neck cancer	0.00274	0.0183	CbGeAlD
Lenalidomide—CDH5—lymphoid tissue—head and neck cancer	0.00256	0.0171	CbGeAlD
Lenalidomide—CRBN—parotid gland—head and neck cancer	0.00252	0.0169	CbGeAlD
Lenalidomide—Thalidomide—CYP1A1—head and neck cancer	0.00247	0.385	CrCbGaD
Lenalidomide—PTGS2—cartilage tissue—head and neck cancer	0.00243	0.0163	CbGeAlD
Lenalidomide—CRBN—saliva-secreting gland—head and neck cancer	0.00242	0.0162	CbGeAlD
Lenalidomide—Pomalidomide—PTGS2—head and neck cancer	0.0024	0.374	CrCbGaD
Lenalidomide—CDH5—thyroid gland—head and neck cancer	0.00232	0.0155	CbGeAlD
Lenalidomide—CDH5—head—head and neck cancer	0.00206	0.0138	CbGeAlD
Lenalidomide—CDH5—S1P2 pathway—MAPK3—head and neck cancer	0.00192	0.0356	CbGpPWpGaD
Lenalidomide—TNFSF11—lymph node—head and neck cancer	0.00192	0.0128	CbGeAlD
Lenalidomide—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—head and neck cancer	0.00191	0.0353	CbGpPWpGaD
Lenalidomide—CRBN—trachea—head and neck cancer	0.00186	0.0125	CbGeAlD
Lenalidomide—CDH5—S1P2 pathway—MAPK1—head and neck cancer	0.00183	0.0338	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—STAT3—head and neck cancer	0.00165	0.0306	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—VEGFA—head and neck cancer	0.00164	0.0304	CbGpPWpGaD
Lenalidomide—CRBN—lymphoid tissue—head and neck cancer	0.00162	0.0109	CbGeAlD
Lenalidomide—CDH5—Cell-cell junction organization—CDH1—head and neck cancer	0.0016	0.0296	CbGpPWpGaD
Lenalidomide—CDH5—S1P2 pathway—PIK3CA—head and neck cancer	0.00159	0.0294	CbGpPWpGaD
Lenalidomide—Thalidomide—PTGS2—head and neck cancer	0.00154	0.241	CrCbGaD
Lenalidomide—CRBN—thyroid gland—head and neck cancer	0.00147	0.00987	CbGeAlD
Lenalidomide—CDH5—lymph node—head and neck cancer	0.00144	0.00965	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—MAPK3—head and neck cancer	0.00139	0.0258	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—MAPK1—head and neck cancer	0.00133	0.0245	CbGpPWpGaD
Lenalidomide—CRBN—head—head and neck cancer	0.00131	0.00876	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—PIK3CA—head and neck cancer	0.0013	0.0241	CbGpPWpGaD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—AKT1—head and neck cancer	0.00122	0.0226	CbGpPWpGaD
Lenalidomide—CDH5—Cell junction organization—CDH1—head and neck cancer	0.00121	0.0224	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—AKT1—head and neck cancer	0.00107	0.0197	CbGpPWpGaD
Lenalidomide—PTGS2—mouth—head and neck cancer	0.000987	0.0066	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—head and neck cancer	0.000942	0.0174	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—AKT1—head and neck cancer	0.00094	0.0174	CbGpPWpGaD
Lenalidomide—CRBN—lymph node—head and neck cancer	0.000916	0.00613	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—MAPK3—head and neck cancer	0.000891	0.0165	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—CDH1—head and neck cancer	0.000863	0.016	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—MAPK1—head and neck cancer	0.000848	0.0157	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—PIK3CA—head and neck cancer	0.000736	0.0136	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VEGFA—head and neck cancer	0.000655	0.0121	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000654	0.0121	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—MAPK3—head and neck cancer	0.00062	0.0115	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—VEGFA—head and neck cancer	0.000619	0.0114	CbGpPWpGaD
Lenalidomide—PTGS2—connective tissue—head and neck cancer	0.000605	0.00405	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—head and neck cancer	0.000601	0.0111	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—MAPK1—head and neck cancer	0.00059	0.0109	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—MAPK3—head and neck cancer	0.000585	0.0108	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CEBPA—head and neck cancer	0.000575	0.0106	CbGpPWpGaD
Lenalidomide—PTGS2—epithelium—head and neck cancer	0.000574	0.00384	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—MAPK1—head and neck cancer	0.000557	0.0103	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—PIK3CA—head and neck cancer	0.000512	0.00947	CbGpPWpGaD
Lenalidomide—PTGS2—trachea—head and neck cancer	0.000508	0.0034	CbGeAlD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCNA1—head and neck cancer	0.000507	0.00937	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—PIK3CA—head and neck cancer	0.000483	0.00894	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—HRAS—head and neck cancer	0.000474	0.00876	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—BCL2—head and neck cancer	0.000471	0.00871	CbGpPWpGaD
Lenalidomide—Haemoglobin—Hydroxyurea—head and neck cancer	0.000469	0.00254	CcSEcCtD
Lenalidomide—Influenza like illness—Docetaxel—head and neck cancer	0.000469	0.00253	CcSEcCtD
Lenalidomide—Haemorrhage—Hydroxyurea—head and neck cancer	0.000467	0.00252	CcSEcCtD
Lenalidomide—Hallucination—Hydroxyurea—head and neck cancer	0.000464	0.00251	CcSEcCtD
Lenalidomide—Colitis—Docetaxel—head and neck cancer	0.000464	0.00251	CcSEcCtD
Lenalidomide—Cardiac arrest—Fluorouracil—head and neck cancer	0.000462	0.0025	CcSEcCtD
Lenalidomide—Candida infection—Docetaxel—head and neck cancer	0.000461	0.00249	CcSEcCtD
Lenalidomide—Ataxia—Fluorouracil—head and neck cancer	0.000457	0.00247	CcSEcCtD
Lenalidomide—Neuropathy—Docetaxel—head and neck cancer	0.000453	0.00245	CcSEcCtD
Lenalidomide—Alopecia—Vinblastine—head and neck cancer	0.000452	0.00244	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—HRAS—head and neck cancer	0.000447	0.00827	CbGpPWpGaD
Lenalidomide—Dry skin—Fluorouracil—head and neck cancer	0.000445	0.00241	CcSEcCtD
Lenalidomide—PTGS2—lymphoid tissue—head and neck cancer	0.000442	0.00296	CbGeAlD
Lenalidomide—CDH5—Cell-Cell communication—PIK3CA—head and neck cancer	0.000438	0.0081	CbGpPWpGaD
Lenalidomide—Neoplasm—Docetaxel—head and neck cancer	0.000437	0.00236	CcSEcCtD
Lenalidomide—Nasopharyngitis—Fluorouracil—head and neck cancer	0.000434	0.00235	CcSEcCtD
Lenalidomide—Pulmonary oedema—Docetaxel—head and neck cancer	0.00043	0.00232	CcSEcCtD
Lenalidomide—Muscular weakness—Fluorouracil—head and neck cancer	0.000428	0.00232	CcSEcCtD
Lenalidomide—Angiopathy—Hydroxyurea—head and neck cancer	0.000424	0.00229	CcSEcCtD
Lenalidomide—Dysphagia—Fluorouracil—head and neck cancer	0.00042	0.00227	CcSEcCtD
Lenalidomide—Sepsis—Docetaxel—head and neck cancer	0.000419	0.00226	CcSEcCtD
Lenalidomide—Chills—Hydroxyurea—head and neck cancer	0.000419	0.00226	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—AKT1—head and neck cancer	0.000418	0.00773	CbGpPWpGaD
Lenalidomide—Ill-defined disorder—Vinblastine—head and neck cancer	0.000413	0.00223	CcSEcCtD
Lenalidomide—Alopecia—Hydroxyurea—head and neck cancer	0.000413	0.00223	CcSEcCtD
Lenalidomide—Anaemia—Vinblastine—head and neck cancer	0.000412	0.00223	CcSEcCtD
Lenalidomide—Angina pectoris—Fluorouracil—head and neck cancer	0.000409	0.00221	CcSEcCtD
Lenalidomide—Erythema—Hydroxyurea—head and neck cancer	0.000406	0.0022	CcSEcCtD
Lenalidomide—Thrombophlebitis—Docetaxel—head and neck cancer	0.000405	0.00219	CcSEcCtD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—head and neck cancer	0.000404	0.00748	CbGpPWpGaD
Lenalidomide—Malaise—Vinblastine—head and neck cancer	0.000402	0.00217	CcSEcCtD
Lenalidomide—Vertigo—Vinblastine—head and neck cancer	0.0004	0.00216	CcSEcCtD
Lenalidomide—Leukopenia—Vinblastine—head and neck cancer	0.000399	0.00216	CcSEcCtD
Lenalidomide—Pancytopenia—Fluorouracil—head and neck cancer	0.000399	0.00215	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—AKT1—head and neck cancer	0.000395	0.0073	CbGpPWpGaD
Lenalidomide—Deafness—Docetaxel—head and neck cancer	0.000392	0.00212	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00039	0.00211	CcSEcCtD
Lenalidomide—Hepatic failure—Docetaxel—head and neck cancer	0.00039	0.00211	CcSEcCtD
Lenalidomide—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000387	0.00209	CcSEcCtD
Lenalidomide—Hypertension—Vinblastine—head and neck cancer	0.000385	0.00208	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000383	0.00207	CcSEcCtD
Lenalidomide—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000377	0.00204	CcSEcCtD
Lenalidomide—Pneumonia—Fluorouracil—head and neck cancer	0.000376	0.00203	CcSEcCtD
Lenalidomide—Anaemia—Hydroxyurea—head and neck cancer	0.000376	0.00203	CcSEcCtD
Lenalidomide—Discomfort—Vinblastine—head and neck cancer	0.000375	0.00203	CcSEcCtD
Lenalidomide—Infestation—Fluorouracil—head and neck cancer	0.000374	0.00202	CcSEcCtD
Lenalidomide—Infestation NOS—Fluorouracil—head and neck cancer	0.000374	0.00202	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CYP1A1—head and neck cancer	0.000371	0.00686	CbGpPWpGaD
Lenalidomide—Atrial fibrillation—Docetaxel—head and neck cancer	0.00037	0.002	CcSEcCtD
Lenalidomide—Visual disturbance—Docetaxel—head and neck cancer	0.00037	0.002	CcSEcCtD
Lenalidomide—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000369	0.00199	CcSEcCtD
Lenalidomide—Myocardial infarction—Fluorouracil—head and neck cancer	0.000367	0.00198	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000367	0.00198	CcSEcCtD
Lenalidomide—Malaise—Hydroxyurea—head and neck cancer	0.000366	0.00198	CcSEcCtD
Lenalidomide—Stomatitis—Fluorouracil—head and neck cancer	0.000365	0.00197	CcSEcCtD
Lenalidomide—Conjunctivitis—Fluorouracil—head and neck cancer	0.000364	0.00197	CcSEcCtD
Lenalidomide—Urinary tract infection—Fluorouracil—head and neck cancer	0.000364	0.00197	CcSEcCtD
Lenalidomide—Leukopenia—Hydroxyurea—head and neck cancer	0.000364	0.00197	CcSEcCtD
Lenalidomide—Cardiac failure—Docetaxel—head and neck cancer	0.000359	0.00194	CcSEcCtD
Lenalidomide—Lethargy—Docetaxel—head and neck cancer	0.000358	0.00193	CcSEcCtD
Lenalidomide—PTGS2—head—head and neck cancer	0.000356	0.00238	CbGeAlD
Lenalidomide—Thrombocytopenia—Vinblastine—head and neck cancer	0.000356	0.00192	CcSEcCtD
Lenalidomide—ABCB1—epithelium—head and neck cancer	0.000355	0.00238	CbGeAlD
Lenalidomide—Epistaxis—Fluorouracil—head and neck cancer	0.000353	0.00191	CcSEcCtD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—head and neck cancer	0.000352	0.00652	CbGpPWpGaD
Lenalidomide—Hyponatraemia—Docetaxel—head and neck cancer	0.000352	0.0019	CcSEcCtD
Lenalidomide—Sinusitis—Fluorouracil—head and neck cancer	0.000351	0.0019	CcSEcCtD
Lenalidomide—Pain in extremity—Docetaxel—head and neck cancer	0.000351	0.00189	CcSEcCtD
Lenalidomide—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000351	0.00189	CcSEcCtD
Lenalidomide—PTGS2—Arachidonic acid metabolism—GPX1—head and neck cancer	0.00035	0.00648	CbGpPWpGaD
Lenalidomide—Agranulocytosis—Fluorouracil—head and neck cancer	0.000349	0.00189	CcSEcCtD
Lenalidomide—PTGS2—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000347	0.00642	CbGpPWpGaD
Lenalidomide—Anorexia—Vinblastine—head and neck cancer	0.000347	0.00187	CcSEcCtD
Lenalidomide—Migraine—Docetaxel—head and neck cancer	0.000345	0.00186	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—KISS1—head and neck cancer	0.000344	0.00636	CbGpPWpGaD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000344	0.00186	CcSEcCtD
Lenalidomide—Discomfort—Hydroxyurea—head and neck cancer	0.000342	0.00185	CcSEcCtD
Lenalidomide—Haemoglobin—Fluorouracil—head and neck cancer	0.000338	0.00183	CcSEcCtD
Lenalidomide—Rhinitis—Fluorouracil—head and neck cancer	0.000337	0.00182	CcSEcCtD
Lenalidomide—Haemorrhage—Fluorouracil—head and neck cancer	0.000336	0.00182	CcSEcCtD
Lenalidomide—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000334	0.00181	CcSEcCtD
Lenalidomide—Pharyngitis—Fluorouracil—head and neck cancer	0.000333	0.0018	CcSEcCtD
Lenalidomide—PTGS2—S1P1 pathway—MAPK3—head and neck cancer	0.000333	0.00617	CbGpPWpGaD
Lenalidomide—Oedema—Hydroxyurea—head and neck cancer	0.000332	0.00179	CcSEcCtD
Lenalidomide—Ataxia—Docetaxel—head and neck cancer	0.00033	0.00178	CcSEcCtD
Lenalidomide—Infection—Hydroxyurea—head and neck cancer	0.000329	0.00178	CcSEcCtD
Lenalidomide—Paraesthesia—Vinblastine—head and neck cancer	0.000327	0.00176	CcSEcCtD
Lenalidomide—Dehydration—Docetaxel—head and neck cancer	0.000326	0.00176	CcSEcCtD
Lenalidomide—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000325	0.00176	CcSEcCtD
Lenalidomide—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000325	0.00175	CcSEcCtD
Lenalidomide—Liver function test abnormal—Docetaxel—head and neck cancer	0.000324	0.00175	CcSEcCtD
Lenalidomide—Skin disorder—Hydroxyurea—head and neck cancer	0.000322	0.00174	CcSEcCtD
Lenalidomide—Dry skin—Docetaxel—head and neck cancer	0.000321	0.00174	CcSEcCtD
Lenalidomide—Abdominal pain upper—Docetaxel—head and neck cancer	0.00032	0.00173	CcSEcCtD
Lenalidomide—PTGS2—S1P1 pathway—MAPK1—head and neck cancer	0.000317	0.00587	CbGpPWpGaD
Lenalidomide—Breast disorder—Docetaxel—head and neck cancer	0.000317	0.00171	CcSEcCtD
Lenalidomide—Anorexia—Hydroxyurea—head and neck cancer	0.000316	0.00171	CcSEcCtD
Lenalidomide—Decreased appetite—Vinblastine—head and neck cancer	0.000316	0.00171	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000316	0.00171	CcSEcCtD
Lenalidomide—Cramp muscle—Docetaxel—head and neck cancer	0.000316	0.00171	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000316	0.00171	CcSEcCtD
Lenalidomide—ABCB1—trachea—head and neck cancer	0.000314	0.0021	CbGeAlD
Lenalidomide—Nasopharyngitis—Docetaxel—head and neck cancer	0.000313	0.00169	CcSEcCtD
Lenalidomide—Constipation—Vinblastine—head and neck cancer	0.000311	0.00168	CcSEcCtD
Lenalidomide—Pain—Vinblastine—head and neck cancer	0.000311	0.00168	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000309	0.00167	CcSEcCtD
Lenalidomide—Dysphagia—Docetaxel—head and neck cancer	0.000303	0.00164	CcSEcCtD
Lenalidomide—Arrhythmia—Fluorouracil—head and neck cancer	0.0003	0.00162	CcSEcCtD
Lenalidomide—Feeling abnormal—Vinblastine—head and neck cancer	0.0003	0.00162	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000297	0.00161	CcSEcCtD
Lenalidomide—Alopecia—Fluorouracil—head and neck cancer	0.000297	0.0016	CcSEcCtD
Lenalidomide—Dyspnoea—Hydroxyurea—head and neck cancer	0.000296	0.0016	CcSEcCtD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—head and neck cancer	0.000296	0.00547	CbGpPWpGaD
Lenalidomide—Angina pectoris—Docetaxel—head and neck cancer	0.000295	0.0016	CcSEcCtD
Lenalidomide—Somnolence—Hydroxyurea—head and neck cancer	0.000295	0.00159	CcSEcCtD
Lenalidomide—Erythema—Fluorouracil—head and neck cancer	0.000293	0.00158	CcSEcCtD
Lenalidomide—Dyspepsia—Hydroxyurea—head and neck cancer	0.000292	0.00158	CcSEcCtD
Lenalidomide—Decreased appetite—Hydroxyurea—head and neck cancer	0.000288	0.00156	CcSEcCtD
Lenalidomide—Pancytopenia—Docetaxel—head and neck cancer	0.000288	0.00156	CcSEcCtD
Lenalidomide—Abdominal pain—Vinblastine—head and neck cancer	0.000287	0.00155	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000286	0.00155	CcSEcCtD
Lenalidomide—Fatigue—Hydroxyurea—head and neck cancer	0.000286	0.00155	CcSEcCtD
Lenalidomide—Pain—Hydroxyurea—head and neck cancer	0.000284	0.00153	CcSEcCtD
Lenalidomide—Constipation—Hydroxyurea—head and neck cancer	0.000284	0.00153	CcSEcCtD
Lenalidomide—Neutropenia—Docetaxel—head and neck cancer	0.000283	0.00153	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—GRP—head and neck cancer	0.000283	0.00524	CbGpPWpGaD
Lenalidomide—Weight increased—Docetaxel—head and neck cancer	0.000276	0.00149	CcSEcCtD
Lenalidomide—Vision blurred—Fluorouracil—head and neck cancer	0.000276	0.00149	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—STAT6—head and neck cancer	0.000275	0.00508	CbGpPWpGaD
Lenalidomide—Weight decreased—Docetaxel—head and neck cancer	0.000274	0.00148	CcSEcCtD
Lenalidomide—ABCB1—lymphoid tissue—head and neck cancer	0.000273	0.00183	CbGeAlD
Lenalidomide—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000273	0.00148	CcSEcCtD
Lenalidomide—Pneumonia—Docetaxel—head and neck cancer	0.000272	0.00147	CcSEcCtD
Lenalidomide—Anaemia—Fluorouracil—head and neck cancer	0.00027	0.00146	CcSEcCtD
Lenalidomide—Infestation NOS—Docetaxel—head and neck cancer	0.00027	0.00146	CcSEcCtD
Lenalidomide—Infestation—Docetaxel—head and neck cancer	0.00027	0.00146	CcSEcCtD
Lenalidomide—Hypersensitivity—Vinblastine—head and neck cancer	0.000268	0.00145	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000268	0.00145	CcSEcCtD
Lenalidomide—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000266	0.00144	CcSEcCtD
Lenalidomide—Renal failure—Docetaxel—head and neck cancer	0.000266	0.00144	CcSEcCtD
Lenalidomide—Myocardial infarction—Docetaxel—head and neck cancer	0.000265	0.00143	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000265	0.00143	CcSEcCtD
Lenalidomide—Stomatitis—Docetaxel—head and neck cancer	0.000263	0.00142	CcSEcCtD
Lenalidomide—Conjunctivitis—Docetaxel—head and neck cancer	0.000263	0.00142	CcSEcCtD
Lenalidomide—Body temperature increased—Hydroxyurea—head and neck cancer	0.000262	0.00142	CcSEcCtD
Lenalidomide—Leukopenia—Fluorouracil—head and neck cancer	0.000262	0.00141	CcSEcCtD
Lenalidomide—Asthenia—Vinblastine—head and neck cancer	0.000261	0.00141	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000256	0.00138	CcSEcCtD
Lenalidomide—Epistaxis—Docetaxel—head and neck cancer	0.000255	0.00138	CcSEcCtD
Lenalidomide—Agranulocytosis—Docetaxel—head and neck cancer	0.000252	0.00136	CcSEcCtD
Lenalidomide—PTGS2—lymph node—head and neck cancer	0.000249	0.00167	CbGeAlD
Lenalidomide—Chest pain—Fluorouracil—head and neck cancer	0.000249	0.00135	CcSEcCtD
Lenalidomide—Myalgia—Fluorouracil—head and neck cancer	0.000249	0.00135	CcSEcCtD
Lenalidomide—Diarrhoea—Vinblastine—head and neck cancer	0.000249	0.00134	CcSEcCtD
Lenalidomide—ABCB1—thyroid gland—head and neck cancer	0.000248	0.00166	CbGeAlD
Lenalidomide—Discomfort—Fluorouracil—head and neck cancer	0.000246	0.00133	CcSEcCtD
Lenalidomide—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000244	0.00132	CcSEcCtD
Lenalidomide—Haemoglobin—Docetaxel—head and neck cancer	0.000244	0.00132	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—YAP1—head and neck cancer	0.000243	0.0045	CbGpPWpGaD
Lenalidomide—Rhinitis—Docetaxel—head and neck cancer	0.000243	0.00131	CcSEcCtD
Lenalidomide—Haemorrhage—Docetaxel—head and neck cancer	0.000243	0.00131	CcSEcCtD
Lenalidomide—Hepatitis—Docetaxel—head and neck cancer	0.000243	0.00131	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—GSTM1—head and neck cancer	0.000242	0.00447	CbGpPWpGaD
Lenalidomide—Hypoaesthesia—Docetaxel—head and neck cancer	0.000241	0.0013	CcSEcCtD
Lenalidomide—Confusional state—Fluorouracil—head and neck cancer	0.000241	0.0013	CcSEcCtD
Lenalidomide—Pharyngitis—Docetaxel—head and neck cancer	0.000241	0.0013	CcSEcCtD
Lenalidomide—Dizziness—Vinblastine—head and neck cancer	0.00024	0.0013	CcSEcCtD
Lenalidomide—Urinary tract disorder—Docetaxel—head and neck cancer	0.00024	0.00129	CcSEcCtD
Lenalidomide—Oedema peripheral—Docetaxel—head and neck cancer	0.000239	0.00129	CcSEcCtD
Lenalidomide—Oedema—Fluorouracil—head and neck cancer	0.000239	0.00129	CcSEcCtD
Lenalidomide—Connective tissue disorder—Docetaxel—head and neck cancer	0.000238	0.00129	CcSEcCtD
Lenalidomide—Asthenia—Hydroxyurea—head and neck cancer	0.000238	0.00129	CcSEcCtD
Lenalidomide—Urethral disorder—Docetaxel—head and neck cancer	0.000238	0.00128	CcSEcCtD
Lenalidomide—Infection—Fluorouracil—head and neck cancer	0.000237	0.00128	CcSEcCtD
Lenalidomide—Nervous system disorder—Fluorouracil—head and neck cancer	0.000234	0.00127	CcSEcCtD
Lenalidomide—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000234	0.00126	CcSEcCtD
Lenalidomide—Visual impairment—Docetaxel—head and neck cancer	0.000234	0.00126	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD2—head and neck cancer	0.000234	0.00432	CbGpPWpGaD
Lenalidomide—Tachycardia—Fluorouracil—head and neck cancer	0.000233	0.00126	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.000232	0.00429	CbGpPWpGaD
Lenalidomide—Vomiting—Vinblastine—head and neck cancer	0.000231	0.00125	CcSEcCtD
Lenalidomide—Erythema multiforme—Docetaxel—head and neck cancer	0.000229	0.00124	CcSEcCtD
Lenalidomide—Headache—Vinblastine—head and neck cancer	0.000228	0.00123	CcSEcCtD
Lenalidomide—Anorexia—Fluorouracil—head and neck cancer	0.000228	0.00123	CcSEcCtD
Lenalidomide—Diarrhoea—Hydroxyurea—head and neck cancer	0.000227	0.00123	CcSEcCtD
Lenalidomide—Eye disorder—Docetaxel—head and neck cancer	0.000227	0.00122	CcSEcCtD
Lenalidomide—Flushing—Docetaxel—head and neck cancer	0.000225	0.00122	CcSEcCtD
Lenalidomide—Cardiac disorder—Docetaxel—head and neck cancer	0.000225	0.00122	CcSEcCtD
Lenalidomide—Hypotension—Fluorouracil—head and neck cancer	0.000223	0.00121	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—GPX1—head and neck cancer	0.000223	0.00412	CbGpPWpGaD
Lenalidomide—ABCB1—head—head and neck cancer	0.00022	0.00147	CbGeAlD
Lenalidomide—Angiopathy—Docetaxel—head and neck cancer	0.00022	0.00119	CcSEcCtD
Lenalidomide—Dizziness—Hydroxyurea—head and neck cancer	0.000219	0.00119	CcSEcCtD
Lenalidomide—Immune system disorder—Docetaxel—head and neck cancer	0.000219	0.00118	CcSEcCtD
Lenalidomide—Mediastinal disorder—Docetaxel—head and neck cancer	0.000219	0.00118	CcSEcCtD
Lenalidomide—Chills—Docetaxel—head and neck cancer	0.000218	0.00118	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000217	0.00118	CcSEcCtD
Lenalidomide—Arrhythmia—Docetaxel—head and neck cancer	0.000217	0.00117	CcSEcCtD
Lenalidomide—Nausea—Vinblastine—head and neck cancer	0.000216	0.00117	CcSEcCtD
Lenalidomide—Insomnia—Fluorouracil—head and neck cancer	0.000216	0.00117	CcSEcCtD
Lenalidomide—Paraesthesia—Fluorouracil—head and neck cancer	0.000214	0.00116	CcSEcCtD
Lenalidomide—Alopecia—Docetaxel—head and neck cancer	0.000214	0.00116	CcSEcCtD
Lenalidomide—Dyspnoea—Fluorouracil—head and neck cancer	0.000213	0.00115	CcSEcCtD
Lenalidomide—Mental disorder—Docetaxel—head and neck cancer	0.000212	0.00115	CcSEcCtD
Lenalidomide—Somnolence—Fluorouracil—head and neck cancer	0.000212	0.00115	CcSEcCtD
Lenalidomide—Erythema—Docetaxel—head and neck cancer	0.000211	0.00114	CcSEcCtD
Lenalidomide—Malnutrition—Docetaxel—head and neck cancer	0.000211	0.00114	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.000211	0.0039	CbGpPWpGaD
Lenalidomide—Vomiting—Hydroxyurea—head and neck cancer	0.000211	0.00114	CcSEcCtD
Lenalidomide—Dyspepsia—Fluorouracil—head and neck cancer	0.00021	0.00114	CcSEcCtD
Lenalidomide—Rash—Hydroxyurea—head and neck cancer	0.000209	0.00113	CcSEcCtD
Lenalidomide—Dermatitis—Hydroxyurea—head and neck cancer	0.000209	0.00113	CcSEcCtD
Lenalidomide—Headache—Hydroxyurea—head and neck cancer	0.000208	0.00112	CcSEcCtD
Lenalidomide—Decreased appetite—Fluorouracil—head and neck cancer	0.000208	0.00112	CcSEcCtD
Lenalidomide—Dysgeusia—Docetaxel—head and neck cancer	0.000207	0.00112	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000206	0.00111	CcSEcCtD
Lenalidomide—Back pain—Docetaxel—head and neck cancer	0.000204	0.0011	CcSEcCtD
Lenalidomide—Pain—Fluorouracil—head and neck cancer	0.000204	0.0011	CcSEcCtD
Lenalidomide—Muscle spasms—Docetaxel—head and neck cancer	0.000203	0.0011	CcSEcCtD
Lenalidomide—Nausea—Hydroxyurea—head and neck cancer	0.000197	0.00106	CcSEcCtD
Lenalidomide—Feeling abnormal—Fluorouracil—head and neck cancer	0.000197	0.00106	CcSEcCtD
Lenalidomide—Anaemia—Docetaxel—head and neck cancer	0.000195	0.00105	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—head and neck cancer	0.000191	0.00354	CbGpPWpGaD
Lenalidomide—Urticaria—Fluorouracil—head and neck cancer	0.00019	0.00102	CcSEcCtD
Lenalidomide—Syncope—Docetaxel—head and neck cancer	0.000189	0.00102	CcSEcCtD
Lenalidomide—Leukopenia—Docetaxel—head and neck cancer	0.000189	0.00102	CcSEcCtD
Lenalidomide—Body temperature increased—Fluorouracil—head and neck cancer	0.000189	0.00102	CcSEcCtD
Lenalidomide—Palpitations—Docetaxel—head and neck cancer	0.000187	0.00101	CcSEcCtD
Lenalidomide—Loss of consciousness—Docetaxel—head and neck cancer	0.000186	0.001	CcSEcCtD
Lenalidomide—Cough—Docetaxel—head and neck cancer	0.000184	0.000996	CcSEcCtD
Lenalidomide—Hypertension—Docetaxel—head and neck cancer	0.000182	0.000985	CcSEcCtD
Lenalidomide—Chest pain—Docetaxel—head and neck cancer	0.00018	0.000971	CcSEcCtD
Lenalidomide—Myalgia—Docetaxel—head and neck cancer	0.00018	0.000971	CcSEcCtD
Lenalidomide—Arthralgia—Docetaxel—head and neck cancer	0.00018	0.000971	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000179	0.000965	CcSEcCtD
Lenalidomide—Hypersensitivity—Fluorouracil—head and neck cancer	0.000176	0.00095	CcSEcCtD
Lenalidomide—Dry mouth—Docetaxel—head and neck cancer	0.000176	0.00095	CcSEcCtD
Lenalidomide—Confusional state—Docetaxel—head and neck cancer	0.000174	0.000939	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	0.000174	0.00321	CbGpPWpGaD
Lenalidomide—Oedema—Docetaxel—head and neck cancer	0.000172	0.000931	CcSEcCtD
Lenalidomide—Infection—Docetaxel—head and neck cancer	0.000171	0.000925	CcSEcCtD
Lenalidomide—Shock—Docetaxel—head and neck cancer	0.00017	0.000916	CcSEcCtD
Lenalidomide—Nervous system disorder—Docetaxel—head and neck cancer	0.000169	0.000913	CcSEcCtD
Lenalidomide—Pruritus—Fluorouracil—head and neck cancer	0.000169	0.000913	CcSEcCtD
Lenalidomide—Thrombocytopenia—Docetaxel—head and neck cancer	0.000169	0.000912	CcSEcCtD
Lenalidomide—Tachycardia—Docetaxel—head and neck cancer	0.000168	0.000909	CcSEcCtD
Lenalidomide—Skin disorder—Docetaxel—head and neck cancer	0.000167	0.000904	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.000164	0.00304	CbGpPWpGaD
Lenalidomide—Anorexia—Docetaxel—head and neck cancer	0.000164	0.000888	CcSEcCtD
Lenalidomide—Diarrhoea—Fluorouracil—head and neck cancer	0.000163	0.000883	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—head and neck cancer	0.000163	0.00302	CbGpPWpGaD
Lenalidomide—Hypotension—Docetaxel—head and neck cancer	0.000161	0.00087	CcSEcCtD
Lenalidomide—Dizziness—Fluorouracil—head and neck cancer	0.000158	0.000853	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000157	0.000848	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	0.000156	0.00289	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	0.000156	0.00289	CbGpPWpGaD
Lenalidomide—Insomnia—Docetaxel—head and neck cancer	0.000156	0.000842	CcSEcCtD
Lenalidomide—Paraesthesia—Docetaxel—head and neck cancer	0.000155	0.000836	CcSEcCtD
Lenalidomide—ABCB1—lymph node—head and neck cancer	0.000154	0.00103	CbGeAlD
Lenalidomide—Dyspnoea—Docetaxel—head and neck cancer	0.000154	0.00083	CcSEcCtD
Lenalidomide—Somnolence—Docetaxel—head and neck cancer	0.000153	0.000828	CcSEcCtD
Lenalidomide—Vomiting—Fluorouracil—head and neck cancer	0.000152	0.00082	CcSEcCtD
Lenalidomide—Dyspepsia—Docetaxel—head and neck cancer	0.000152	0.00082	CcSEcCtD
Lenalidomide—Rash—Fluorouracil—head and neck cancer	0.000151	0.000813	CcSEcCtD
Lenalidomide—Dermatitis—Fluorouracil—head and neck cancer	0.00015	0.000813	CcSEcCtD
Lenalidomide—Decreased appetite—Docetaxel—head and neck cancer	0.00015	0.000809	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.00015	0.00277	CbGpPWpGaD
Lenalidomide—Headache—Fluorouracil—head and neck cancer	0.00015	0.000808	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000149	0.000804	CcSEcCtD
Lenalidomide—Fatigue—Docetaxel—head and neck cancer	0.000149	0.000803	CcSEcCtD
Lenalidomide—Constipation—Docetaxel—head and neck cancer	0.000147	0.000796	CcSEcCtD
Lenalidomide—Pain—Docetaxel—head and neck cancer	0.000147	0.000796	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—BCL2—head and neck cancer	0.000143	0.00265	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Docetaxel—head and neck cancer	0.000142	0.000767	CcSEcCtD
Lenalidomide—Nausea—Fluorouracil—head and neck cancer	0.000142	0.000766	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000141	0.000761	CcSEcCtD
Lenalidomide—Body temperature increased—Docetaxel—head and neck cancer	0.000136	0.000736	CcSEcCtD
Lenalidomide—Abdominal pain—Docetaxel—head and neck cancer	0.000136	0.000736	CcSEcCtD
Lenalidomide—Hypersensitivity—Docetaxel—head and neck cancer	0.000127	0.000686	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000127	0.00234	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	0.000126	0.00232	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP8—head and neck cancer	0.000124	0.0023	CbGpPWpGaD
Lenalidomide—Asthenia—Docetaxel—head and neck cancer	0.000124	0.000668	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCND1—head and neck cancer	0.000123	0.00228	CbGpPWpGaD
Lenalidomide—Pruritus—Docetaxel—head and neck cancer	0.000122	0.000659	CcSEcCtD
Lenalidomide—Diarrhoea—Docetaxel—head and neck cancer	0.000118	0.000637	CcSEcCtD
Lenalidomide—Dizziness—Docetaxel—head and neck cancer	0.000114	0.000616	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—UROD—head and neck cancer	0.000114	0.0021	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOTCH1—head and neck cancer	0.00011	0.00203	CbGpPWpGaD
Lenalidomide—Vomiting—Docetaxel—head and neck cancer	0.00011	0.000592	CcSEcCtD
Lenalidomide—Rash—Docetaxel—head and neck cancer	0.000109	0.000587	CcSEcCtD
Lenalidomide—Dermatitis—Docetaxel—head and neck cancer	0.000109	0.000587	CcSEcCtD
Lenalidomide—Headache—Docetaxel—head and neck cancer	0.000108	0.000583	CcSEcCtD
Lenalidomide—Nausea—Docetaxel—head and neck cancer	0.000102	0.000553	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—head and neck cancer	9.62e-05	0.00178	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL2—head and neck cancer	9.4e-05	0.00174	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—head and neck cancer	9.38e-05	0.00173	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	9.23e-05	0.00171	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	9.03e-05	0.00167	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	8.98e-05	0.00166	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	8.81e-05	0.00163	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	8.66e-05	0.0016	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—UROD—head and neck cancer	8.05e-05	0.00149	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	7.99e-05	0.00148	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—head and neck cancer	7.75e-05	0.00143	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MAPK3—head and neck cancer	7.73e-05	0.00143	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2—head and neck cancer	7.54e-05	0.0014	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	7.43e-05	0.00137	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MAPK1—head and neck cancer	7.36e-05	0.00136	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—head and neck cancer	7.36e-05	0.00136	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—head and neck cancer	7.35e-05	0.00136	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTEN—head and neck cancer	7.1e-05	0.00131	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—head and neck cancer	6.41e-05	0.00119	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	6.38e-05	0.00118	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STAT3—head and neck cancer	6.35e-05	0.00117	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—head and neck cancer	6.18e-05	0.00114	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	6.16e-05	0.00114	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	6.14e-05	0.00114	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MAPK3—head and neck cancer	6.06e-05	0.00112	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	5.89e-05	0.00109	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MAPK1—head and neck cancer	5.77e-05	0.00107	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGFR—head and neck cancer	5.77e-05	0.00107	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	5.56e-05	0.00103	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	5.27e-05	0.000974	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	5.26e-05	0.000973	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	5.01e-05	0.000926	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CA—head and neck cancer	5.01e-05	0.000926	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	5.01e-05	0.000926	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	5.01e-05	0.000926	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	5.01e-05	0.000926	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	4.96e-05	0.000917	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—head and neck cancer	4.84e-05	0.000896	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NAT2—head and neck cancer	4.72e-05	0.000872	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HRAS—head and neck cancer	4.63e-05	0.000857	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	4.52e-05	0.000836	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	4.37e-05	0.000807	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	4.34e-05	0.000803	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	4.2e-05	0.000777	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—DPYD—head and neck cancer	4.14e-05	0.000765	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—head and neck cancer	4.09e-05	0.000757	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	3.94e-05	0.000729	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—YAP1—head and neck cancer	3.92e-05	0.000726	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	3.73e-05	0.00069	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	3.55e-05	0.000656	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.55e-05	0.000656	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	3.55e-05	0.000656	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NAT2—head and neck cancer	3.34e-05	0.000618	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	3.08e-05	0.00057	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	2.98e-05	0.000551	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—DPYD—head and neck cancer	2.93e-05	0.000542	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—YAP1—head and neck cancer	2.78e-05	0.000514	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.57e-05	0.000476	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	2.52e-05	0.000465	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TYMS—head and neck cancer	2.36e-05	0.000436	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTM1—head and neck cancer	2.33e-05	0.000431	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GPX1—head and neck cancer	2.23e-05	0.000413	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1A1—head and neck cancer	2.21e-05	0.000408	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOTCH1—head and neck cancer	2.11e-05	0.000391	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.81e-05	0.000335	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TYMS—head and neck cancer	1.67e-05	0.000309	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTM1—head and neck cancer	1.65e-05	0.000305	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GPX1—head and neck cancer	1.58e-05	0.000292	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1A1—head and neck cancer	1.57e-05	0.000289	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—head and neck cancer	1.37e-05	0.000253	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—head and neck cancer	1.22e-05	0.000226	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK3—head and neck cancer	1.17e-05	0.000216	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—head and neck cancer	1.15e-05	0.000212	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK1—head and neck cancer	1.11e-05	0.000206	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—head and neck cancer	1.11e-05	0.000206	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—head and neck cancer	9.65e-06	0.000178	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—head and neck cancer	9.31e-06	0.000172	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—head and neck cancer	8.92e-06	0.000165	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—head and neck cancer	8.12e-06	0.00015	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—head and neck cancer	8.08e-06	0.000149	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—head and neck cancer	7.88e-06	0.000146	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—head and neck cancer	6.6e-06	0.000122	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—head and neck cancer	5.73e-06	0.000106	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—head and neck cancer	4.68e-06	8.65e-05	CbGpPWpGaD
